- 23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
- AbbVie Showcases Advancement of Solid Tumor Pipeline with New Data in Tumor Types with High Unmet Needs
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study
- Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC
- Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Amgen presents data from multiple early-stage clinical trials
- Antennova to Present Latest Data of ATN-037
- Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Ph 1/2 IL-Believe Trial
- Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST
- Avacta Reports Updated Ph 1 Clinical Data of AVA6000 Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
- Bayer presents extensive new data from its oncology portfolio
- BioAtla presents poster on Ph 2 trial of ozuriftamab vedotin (BA3021) in patients with R/M SCCHN
- BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio
- Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations
- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
- Bristol Myers Squibb to Present Data from Ph 2 RELATIVITY-104 trial exploring the combination of nivolumab, relatlimab (1:1) and chemotherapy as first-line treatment for stage IV or recurrent NSCLC
- C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Ph 1 Trial in BRAF V600 Mutant Solid Tumors
- Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study
- Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors
- Elevar Therapeutics Reports Advances in HCC and Other Oncology Clinical Programs for Rivoceranib Plus Camrelizumab
- Enhertu showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
- ESSA Pharma Presents Updated Ph 1/2 Masofaniten (EPI-7386) Clinical Data
- Evaxion reports 69% ORR in Ph 2 trial of EVX-01
- Exelixis Announces Final Results from Ph 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors
- Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020
- HotSpot Therapeutics Presents First-in-Human Ph 1 Clinical Data on CBL-B Inhibitor, HST-1011
- Imfinzi perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemo alone in muscle-invasive bladder cancer in the NIAGARA Ph 3 trial
- Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
- Immatics Presents Clinical Proof-of-Concept Data from Ongoing Ph 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8
- Immunocore presents Ph 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
- ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
- Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
- Incyte’s Retifanlimab (Zynyz®) Extends PFS in Patients with Squamous Cell Anal Carcinoma (SCAC)
- Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Ph 1/2 Clinical Trial
- IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the 1L Treatment of Advanced Head and Neck Cancer
- iTeos Announces Clinically Meaningful ORR Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in 1L PD-L1 High NSCLC Patients
- Jazz Pharmaceuticals Presents Updated Ph 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
- KEYTRUDA + Chemo Before Surgery and Continued as monotherapy After Surgery Reduced Risk of Death by 34% vs neoadjuvant Chemo in High-Risk Early-Stage TNBC
- KEYTRUDA + CRT Reduced Risk of Death by 33% vs CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
- KEYTRUDA + LENVIMA + TACE Significantly Improved PFS vs TACE Alone in Patients With Unresectable, Non-Metastatic HCC
- KEYTRUDA + Trastuzumab and Chemo Significantly Improved OS vs Trastuzumab and Chemo Alone in 1L Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
- Lantheus Presents Results from the Primary Analysis of Ph 3 Pivotal SPLASH Trial in PSMA-Positive mCRPC
- MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients
- MediLink presents YL201 (B7H3 ADC) with over 6-months PFS in SCLC, and showing pan-tumor benefits
- Medivir to present mature clinical data for fostrox + Lenvima
- NeoImmuneTech Presents Promising Interim Results of CAR-T Combination with its NT-I7 Asset
- New data from TAR-200 Ph 2b SunRISe-1 study show 84% CRR in patients with high-risk NMIBC
- Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
- NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients
- Nuvalent Highlights Presentation of Clinical Data for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
- Nxera’s Partner Cancer Research UK to Present on Ph 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732
- PDS Biotech to Present Updated VERSATILE-002 Data
- Pfizer’s BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant mNSCLC
- Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies of Taletrectinib in Patients with Advanced ROS1-positive NSCLC announced
- Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Ph 1 Trial
- Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma
- RYBREVANT (amivantamab-vmjw) + chemo show 49% ORR in metastatic colorectal cancer
- RYBREVANT (amivantamab-vmjw) + chemo shows positive OS trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
- Scorpion Therapeutics Presents Initial Clinical Data from Ph 1/2 Trial of STX-478 Demonstrating Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors
- Sutro Biopharma Announces Updated Data from Ph 1b Study of Luvelta in Combination with Bevacizumab
- Ten-Year Data for KEYTRUDA Demonstrates Sustained OS Benefit vs Ipilimumab in Advanced Melanoma
- TILT Biotherapeutics Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen
- TORL BioTherapeutics Announces Initial Results of Novel Claudin 6 (CLDN6) Targeted Antibody Drug Conjugate (ADC) TORL-1-23
- Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Ph I/IIa Trial in Solid Tumors that Failed Previous Treatments
- Ultimovacs Announces Updated Data Analysis on UV1 Ph II NIPU Trial in Mesothelioma
Menu
